The firm creates solutions in containment technology, and have established themselves as a leading valve manufacturer as demand for the company’s devices grows worldwide.
The decision to relocate to a larger premises in Speke, Liverpool, was made to help them compete more effectively in the growing aseptic bio-pharma market.
The company is currently the number two manufacturer in the world for containment valves with a 16% market share, and are investing heavily in product development to become the major player for the technology, which is used for transferring raw materials safely and efficiently.
ChargePoint’s new hub is a 27,000sq ft. production and office space and has been fitted out with more than £1m worth of technology to manufacture the devices that are transforming the way medicines and vaccines are processed.
Manging director Chris Eccles said: “Our move is in line with both our growth and our ambition and drive to offer the highest quality products for sectors that need to use containment transfers.
“We have invested in state-of-the art technology to improve our unique and progressive devices and this commitment will be evident in the technology in development at present.
“The first quarter of 2016 showed phenomenal growth for the company and we have adapted to the demand around the world for our products. We want to show the world that we are a high precision manufacturing company surrounded by a cluster of world leading biopharma businesses in Speke and are now targeting an even larger market share.”
Asia’s ambitions to become the major player in global pharma has caused demand for the AseptiSafe valve to grow and ChargePoint have recorded a bumper year for sales so far.
Success of their revolutionary AseptiSafe and high containment PharmaSafe Pro valves accounted for a 386 per cent increase in sales in China and 150 per cent growth in new equipment sales in Asia.